Coeptis Technologies Signs Binding Letter of Intent to
Acquire Key Assets from a Risk Mitigation Software Company with
10,000 customers in over 100 countries, Expanding into
the Booming Data Security Sector following the upcoming acquisition
of NexGenAI Affiliates Network
WEXFORD,
Pa., Dec. 12, 2024 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or
"Coeptis"), a biopharmaceutical company focused on pioneering cell
therapy platforms for cancer, autoimmune, and infectious diseases,
is excited to announce the official launch of Coeptis Technologies,
a new division aimed at diversifying and enhancing the company's
growth potential. This strategic move underscores Coeptis'
commitment to maximizing shareholder value and capitalizing on
high-growth opportunities across different sectors.
In line with this initiative, Coeptis Technologies has
signed a binding Letter of Intent (LOI) with a Risk Mitigation
Software Company who is a leading company in the data security
software industry with over 10,000 customers in over 100 countries.
This LOI outlines the acquisition of significant technology assets,
representing a key step in broadening our operational scope and
entering the burgeoning data security market.
The acquisition will involve the transfer of their proprietary
technologies, including its Data Placement Manager and Sensitive
Content Manager solutions, to Coeptis' newly established
technology subsidiary. This development not only positions Coeptis
as a formidable player in the data security field but also signals
our dedication to innovation and long-term value creation for our
shareholders. The transaction is anticipated to close upon the
finalization of definitive agreements. The current President and
CEO of the Risk Mitigation Software Company, will join Coeptis
management team to lead this new technology division, ensuring that
Coeptis leadership remains focused on both our biotechnology assets
and the expansion into technology without distraction. This
strategic move underscores Coeptis' commitment to maximizing
shareholder value and capitalizing on high-growth opportunities
across different sectors.
Dave Mehalick, President and CEO
of Coeptis Therapeutics, commented, "We are embarking on an
exciting journey of expansion that will not only enhance our
presence in the biopharmaceutical sector but also venture into the
high-growth technology sector. By establishing Coeptis
Technologies, we are strategically positioning ourselves to
leverage the unique opportunities present in these two dynamic
industries. Our commitment to deliver unprecedented value to our
shareholders is stronger than ever as we pursue innovative
solutions that address the evolving needs of the market."
Dave Mehalick continued, "This
acquisition represents a significant milestone in Coeptis'
strategic evolution. By integrating the high-value technology
assets of this new acquisition, we are obtaining well-established,
revenue-generating assets that will enable us to position ourselves
for long-term growth in the rapidly expanding data security
industry. The acquisition will keep our new technology team very
busy in the coming months as they bring over 10,000 customers in
over 100 countries to Coeptis Technologies and they provide a
modern approach to data governance and security by identifying and
protecting all sensitive data regardless of location, platform, or
format. Their framework helps customers prioritize risk, identify
security gaps, and implement effective data protection and privacy
management strategies. The addition of these innovative data
security solutions will not only diversify our portfolio but also
allow us to explore new markets. We are particularly thrilled to
welcome its CEO to our leadership team, as his expertise will be
pivotal in maximizing the value of these assets and driving our
next phase of growth, which aligns with our recently announced
upcoming acquisition of NexGenAI Affiliates Network. More
information on this acquisition will be announced in the coming
weeks."
Dave Mehalick also commented on
the NexGenAI acquisition, stating, "We are excited to integrate
NexGenAI Affiliates Network and its groundbreaking AI and
RPA-driven tools into our new technology division. This integration
is poised to enhance the performance of both our biotechnology and
technology sectors. In highly competitive industries such as
biotech, pharma, and MLM, where regulatory challenges are complex,
having advanced tools to optimize marketing, streamline operations,
and drive measurable results is not just beneficial—it's essential
for our success."
The asset acquisition of the Risk Mitigation Software Company is
subject to customary closing conditions, including the execution of
definitive agreements and requisite approvals by both parties.
Coeptis anticipates completing this transaction in early 2025.
This strategic expansion into Coeptis Technologies comes at a
pivotal time when the technology sector continues to experience
rapid growth, with many of the market's top-performing stocks being
technology-driven. By leveraging the innovative AI and RPA-driven
tools from NexGenAI and the transformative data security
technologies from the upcoming acquisition, Coeptis is not only
diversifying its capabilities but is also positioning itself to
thrive in one of the most dynamic and lucrative industries.
About Coeptis Therapeutics Holdings, Inc.:
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries
including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical company
developing innovative cell therapy platforms for cancer,
autoimmune, and infectious diseases that have the potential to
disrupt conventional treatment paradigms and improve patient
outcomes. Coeptis' product portfolio is highlighted by assets
licensed from Deverra Therapeutics, including an allogeneic
cellular immunotherapy platform and DVX201, a clinical-stage,
unmodified natural killer cell therapy technology. Additionally,
Coeptis is developing a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and the GEAR cell therapy and
companion diagnostic platforms in collaboration with VyGen-Bio and
leading medical researchers at the Karolinska
Institute. The Company is headquartered in Wexford, PA. For more information on Coeptis
visit [https://coeptistx.com/](https://coeptistx.com/).
About NexGenAI:
NexGenAI Holding Group Inc., along with its majority-owned
subsidiary NexGenAI Solutions Group, Inc., has developed a
proprietary suite of advanced tools that power the NexGenAI
Affiliates Network platform. These tools, featuring AI-driven
marketing software and robotic process automation capabilities, are
designed to optimize campaigns, streamline operations, and provide
actionable, data-driven insights. NexGenAI's platform provides
cutting-edge AI-driven solutions that revolutionize business
operations across various sectors. By leveraging artificial
intelligence, NexGenAI empowers companies to automate processes,
optimize efficiency, and drive sustainable growth. For more
information on NexGenAI, visit [nexgenai.io](nexgenai.io).
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Capital Market; (2) the risk that the integration of the Deverra
licensed assets will disrupt current plans and operations of the
Company; (3) the inability to recognize the anticipated benefits of
the newly-licensed assets, which may be affected by, among other
things, competition, the ability of the Company to grow and manage
growth economically and hire and retain key employees; (4) the
risks that the Company's products in development or the
newly-licensed assets fail clinical trials or are not approved by
the U.S. Food and Drug Administration or other applicable
regulatory authorities; (5) costs related to integrating the
newly-licensed Deverra assets and pursuing the contemplated asset
development paths; (6) changes in applicable laws or regulations;
(7) the possibility that the Company may be adversely affected by
other economic, business, and/or competitive factors; and (8) the
impact of the global COVID-19 pandemic on any of the foregoing
risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC").
The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks
including, but not limited, to those risks contained or to be
contained in reports and other filings filed by the Company with
the SEC. For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings made or to be made with the SEC, which are
available for review at www.sec.gov. We undertake no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof unless required
by applicable laws, regulations, or rules.
Contacts
For Coeptis Therapeutics, Inc.:
IR@coeptistx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-unveils-new-technology-division-coeptis-technologies-302329739.html
SOURCE Coeptis Therapeutics, Inc.